Join
Live feed
·
PRReleasevia Quantisnow
Salarius Pharmaceuticals Inc. logo

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

ByQuantisnow·Wall Street's wire, on your screen.
SLRX· Salarius Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLRX (Salarius Pharmaceuticals Inc.) and more on Quantisnow.